** Drug developer ARS Pharmaceuticals' SPRY.O shares rise 18.8% to $13.84
** Co reports Q4 net income of $49.9 million vs. loss estimate of $14.4 million, according to data compiled by LSEG
** Co posts Q4 revenue of $86.6 million, beating analysts' estimates of $15.8 million
** Profit boosted by partnership revenue from drug developer ALK-Abelló to commercialise allergic reaction nasal spray, neffy, in Europe, Canada and outside of U.S.
** SPRY received a non-refundable, upfront cash payment of $145 million from ALK and, of the total cash payment, $73.5 million was included in SPRY's Q4 revenue
** Up to last close, SPRY had risen 37.7% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。